Ursula Wiedermann (born 5 August 1965)[1] is an Austrian medical scientist who has made significant contributions in the field of allergies and of cancer immunotherapy.
[7] In 2012 the Wiedermann lab showed that a fusion protein containing several allergens could treat birch pollen-related food allergy, in which patients are allergic to homologues of Bet v I.
[8] Also in 2012 the Wiedermann lab showed in mice that perinatal administration of Lactobacillus paracasei to pregnant and lactating mothers could protect against the development of airway inflammation in offspring.
[9] Beginning around 2004 Wiedermann began to working on the technology that evolved into HER-Vaxx, a B cell peptide cancer immunotherapy that could induce an antibody response targeting HER-2 overexpressing tumours.
Following on from favourable pre-clinical data,[10] Wiedermann et al. ran a small 10-patient safety study of HER-Vaxx in ten patients with Stage IV metastatic breast cancer, albeit with low HER-2 expression.